Related Experiment Video
Updated: Jun 4, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Epidemiology, clinical picture and management of atrial fibrillation]
1Neurologische Abteilung, Asklepios Klinik Altona, Hamburg, Deutschland. j.roether@asklepios.com
Insights
Atrial fibrillation (AF) is a common heart rhythm disorder increasing stroke risk. Oral anticoagulants and new drugs like dronedarone help prevent stroke in AF patients.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Context:
- Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, affecting about 1% of adults, with prevalence rising sharply with age.
- AF significantly elevates risks of cardiovascular mortality, morbidity, and particularly stroke, which is often more severe and fatal in affected individuals.
Purpose:
- To review the primary therapeutic strategies for managing atrial fibrillation (AF).
- To highlight the role of oral anticoagulants and novel antiarrhythmic drugs in preventing stroke.
- To underscore the underutilization of Vitamin K antagonists (VKAs) despite their efficacy.
Summary:
- Mainstay treatments for AF include oral anticoagulation for thromboembolism prevention and rate or rhythm control.
- Vitamin K antagonists are effective in reducing stroke risk but are not widely used.
- Dronedarone represents a significant advancement as the first antiarrhythmic drug demonstrated to lower stroke rates.
Impact:
- Improved understanding of AF management options and their associated risks.
- Emphasis on optimizing anticoagulation strategies for AF patients to reduce stroke incidence.
- Introduction of new therapeutic avenues, like dronedarone, for stroke risk reduction in AF.
Abstract:
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affects approximately 1% of adults and prevalence increases with age. Nine per cent of those aged 80 years and older have AF. AF is associated with increased cardiovascular mortality and morbidity, including stroke.Stroke in patients with AF is more severe and more likely to be fatal. Prevention of thromboembolism with oral anticoagulants and rate or rhythm control are the main therapeutic strategies for patients with AF. Vitamin K antagonists reduce the risk of stroke in patients with AF, however are underutilized. Dronedarone is the first antiarrhythmic drug that reduces the stroke rate.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Mitral Stenosis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Endocarditis III: Medical Management
Rheumatic Heart Disease IV: Nursing Management

